Table 4

SIR for subsequent ischemic stroke of patients with IMD
Follow-up interval (years)
<1 1-5 5-10 > = 10 All
Immune-mediated diseases O SIR 95% CI O SIR 95% CI O SIR 95% CI O SIR 95% CI O SIR 95% CI
Addison´s disease 14 2.71 1.48 4.56 28 1.17 0.78 1.69 30 1.90 1.28 2.72 11 0.97 0.48 1.74 83 1.48 1.18 1.83
Amyotrophic lateral sclerosis 7 0.53 0.21 1.10 16 1.52 0.87 2.47 7 1.77 0.70 3.67 2 1.15 0.11 4.23 32 1.09 0.74 1.54
Ankylosing spondylitis 8 1.62 0.69 3.21 44 1.55 1.13 2.08 24 0.98 0.63 1.46 35 1.08 0.75 1.50 111 1.23 1.01 1.48
Autoimmune hemolytic anemia 4 1.45 0.38 3.75 12 1.00 0.51 1.75 19 2.51 1.51 3.93 5 1.23 0.39 2.90 40 1.51 1.08 2.06
Behcet´s disease 1 4.00 0.00 22.93 1 0.65 0.00 3.70 0 1 1.43 0.00 8.19 3 0.78 0.15 2.29
Celiac disease 9 2.17 0.99 4.14 29 1.28 0.86 1.84 21 1.17 0.72 1.78 26 1.47 0.96 2.15 85 1.36 1.09 1.68
Chorea minor 0 1 2.27 0.00 13.03 0 0 1 1.11 0.00 6.37
Crohn disease 49 2.15 1.59 2.84 160 1.33 1.13 1.55 103 1.11 0.91 1.35 97 1.15 0.93 1.40 409 1.28 1.16 1.41
Diabetes mellitus type I 1 6.25 0.00 35.83 2 0.45 0.04 1.65 5 2.75 0.87 6.46 17 5.00 2.91 8.02 25 2.54 1.64 3.76
Discoid lupus erythematosus 3 4.23 0.80 12.51 3 0.99 0.19 2.92 1 0.47 0.00 2.70 3 1.55 0.29 4.60 10 1.28 0.61 2.37
Grave´s disease 101 2.15 1.76 2.62 402 1.39 1.26 1.53 348 1.36 1.22 1.51 276 1.27 1.12 1.43 1127 1.39 1.31 1.48
Hashimoto´s thyroiditis 77 2.99 2.36 3.74 211 1.73 1.50 1.98 115 1.39 1.14 1.67 82 1.28 1.02 1.59 485 1.64 1.50 1.80
Immune thrombocytopenic purpura 16 2.35 1.34 3.83 55 1.77 1.33 2.30 19 0.94 0.57 1.48 14 1.20 0.65 2.01 104 1.49 1.22 1.81
Localized scleroderma 2 1.28 0.12 4.71 13 1.25 0.66 2.14 18 1.72 1.01 2.72 11 1.04 0.51 1.86 44 1.33 0.97 1.79
Lupoid hepatitis 3 4.48 0.84 13.25 4 1.98 0.52 5.12 0 0 7 2.10 0.83 4.36
Multiple sclerosis 40 3.05 2.18 4.15 73 1.09 0.85 1.37 55 1.11 0.83 1.44 35 0.95 0.66 1.32 203 1.22 1.06 1.40
Myasthenia gravis 6 1.01 0.36 2.21 38 1.36 0.96 1.87 23 1.20 0.76 1.80 13 1.08 0.57 1.85 80 1.23 0.97 1.53
Pernicious anemia 25 1.56 1.01 2.31 138 1.49 1.25 1.76 89 1.23 0.99 1.52 74 1.44 1.13 1.80 326 1.40 1.25 1.56
Polyarteritis nodosa 5 1.23 0.39 2.89 20 1.30 0.79 2.02 11 1.05 0.52 1.88 10 1.13 0.54 2.08 46 1.19 0.87 1.58
Polymyalgia rheumatica 165 1.76 1.50 2.05 761 1.50 1.39 1.61 529 1.54 1.41 1.68 322 1.53 1.37 1.71 1777 1.54 1.47 1.61
Polymyositis/ dermatomyositis 10 3.46 1.65 6.39 13 1.19 0.63 2.03 6 1.07 0.38 2.34 5 1.73 0.55 4.07 34 1.52 1.05 2.13
Primary biliary cirrhosis 4 1.54 0.40 3.98 11 1.45 0.72 2.60 4 0.91 0.24 2.35 1 2.17 0.00 12.46 20 1.33 0.81 2.05
Psoriasis 44 1.92 1.39 2.58 217 1.65 1.44 1.89 163 1.53 1.30 1.78 144 1.41 1.19 1.66 568 1.56 1.44 1.70
Reiter´s disease 0 5 2.02 0.64 4.76 6 2.47 0.89 5.41 2 0.56 0.05 2.07 13 1.47 0.78 2.52
Rheumatic fever 5 3.91 1.23 9.19 10 1.66 0.79 3.06 14 3.04 1.65 5.11 7 1.81 0.72 3.75 36 2.28 1.59 3.16
Rheumatoid arthritis 345 2.08 1.86 2.31 1266 1.66 1.57 1.75 663 1.45 1.34 1.56 326 1.30 1.16 1.45 2600 1.59 1.53 1.65
Sarcoidosis 9 0.97 0.44 1.85 70 1.43 1.12 1.81 51 1.12 0.83 1.47 56 1.08 0.81 1.40 186 1.19 1.03 1.38
Sjögren´s syndrome 10 2.57 1.22 4.75 28 1.38 0.92 1.99 15 0.96 0.54 1.59 15 1.26 0.70 2.08 68 1.31 1.02 1.67
Systemic lupus erythematosus 19 2.21 1.33 3.46 88 2.33 1.87 2.87 54 1.92 1.44 2.51 30 1.26 0.85 1.80 191 1.94 1.68 2.24
Systemic sclerosis 11 1.90 0.94 3.41 28 1.22 0.81 1.77 11 1.19 0.59 2.14 2 0.39 0.04 1.43 52 1.21 0.90 1.58
Ulcerative colitis 71 2.15 1.68 2.71 231 1.27 1.11 1.45 162 1.09 0.92 1.27 146 1.05 0.89 1.24 610 1.21 1.12 1.31
Wegener´s granulomatosis 11 1.66 0.82 2.98 12 0.47 0.24 0.83 26 1.54 1.00 2.25 12 1.69 0.87 2.96 61 1.09 0.83 1.40
All 1075 2.02 1.90 2.14 3990 1.50 1.46 1.55 2592 1.38 1.33 1.43 1780 1.29 1.23 1.35 9437 1.46 1.43 1.49

O = observed number of cases; SIR = standardized incidence ratio; CI = confidence interval.

Bold type: 95% CI does not include 1.00.

Adjusted for age, period, socioeconomic status, region of residence, hospitalization of chronic lower respiratory diseases, obesity, alcoholism, hypertension, diabetes, atrial fibrillation, heart failure, renal disease, sepsis, and coronary heart disease.

Zöller et al.

Zöller et al. BMC Neurology 2012 12:41   doi:10.1186/1471-2377-12-41

Open Data